Abstract
Immature granulocytes (IGs) have significance for the diagnosis of myeloid neoplasms (MNs). The current study aims to use a hematology analyzer to evaluate the accuracy of IG parameters in MNs. Blood specimens from 388 patients with MN, 524 with non-hematological neoplasms (non-HNs), including 109 patients with inflammation and 68 undergoing G-CSF administration, and 500 healthy control subjects were analyzed. IG parameters was assayed by Sysmex XN-9000 (XN) and compared with manual assessments. A high level of agreement between IG% derived from XN and manual measurements for MN patients (r = 0.828, p < 0.0001) was revealed but only a moderate correlation for acute myeloid leukemia patients (AML; r = 0.597; p < 0.0001). Bland–Altman bias analysis was conducted, and the results showed that differences in IG% from XN and manual analysis for MN patients were considered clinically insignificant. ROC analysis demonstrated a good performance of IG# (AUC = 0.842) and IG% (AUC = 0.885) assessed by XN for MN patients with cut-off values of 0.200 × 109/L and 1.95%, respectively. IG parameters from Sysmex XN analyzer are helpful for screening of MNs even though granulocyte morphological abnormalities may interfere with IG parameter accuracy.
Similar content being viewed by others
Introduction
Immature granulocytes (IGs) comprise promyelocytes, myelocytes, and metamyelocytes [1]. Such cells are seldom seen in the peripheral blood (PB) of healthy subjects, except in certain physiological states and conditions, such as pregnancy or the neonatal period [2,3,4]. By contrast, IGs are found in patients’ PB in the following pathological conditions: acute infection, inflammation, tissue injury, intravascular hemolysis, acute hemorrhage, non-hematopoietic malignant tumor, hematological neoplasms and in those receiving granulocyte colony-stimulating factor (G-CSF) or granulocyte–macrophage colony-stimulating factor (GM-CSF) [5,6,7,8,9,10,11,12,13]. For patients undergoing G-CSF or GM-CSF treatment, IGs act as sensitive indices to indicate granulocytic hematopoietic recovery [12, 13]. IGs are also seen in patients with myeloid neoplasms (MNs), such as acute myeloid leukemia (AML), myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS), and myelodysplastic/myeloproliferative neoplasms (MDS/MPN), and their presence can be used for diagnosis. The conditions of chronic myeloid leukemia (CML) and primary myelofibrosis (PMF) are particularly associated with an increase in IG level [11].
Prior to the availability of the automated hematology analyzer, Sysmex XN series, other analyzers, including Sysmex XS, XT, and XE series, were used to sort cells for research purposes [6, 14]. The Sysmex XN analyzer uses one of the six white blood cell (WBC) differential parameters in the WBC differential (WDF) channel to sort IGs. Erythrocytes are lysed by lysercell WDF which permeates the leukocyte membrane to allow fluorescent staining of nucleic acids by fluorocell™ WDF. A semiconductor laser is then used to detect cells by flow cytometry. A combination of side scatter light (SSC), reflecting complexity of intracellular structures, side fluorescence light (SFL), reflecting fluorescence intensity, and forward scatter light (FSC), to measure cell size, is combined by an intelligent gating algorithm provided by 00-19E (Build 2) IPU version software to judge WBC type. The WDF scattergram shows IGs as dark blue dots above neutrophils. The Q-flag represents the healthy maximal limit of IGs and, above this threshold, “IG present” is indicated. Previous studies have reported general evaluation of Sysmex XN performance in measuring IG parameters [15,16,17], but application of this approach to MNs has been neglected.
The current study aimed to investigate Sysmex XN series performance in IG quantification in various MNs by comparison with manual measurements. Evaluation of the suitability of the Sysmex XN analyzer in reliable detection of IGs in PB and screening for MNs was assessed.
Materials and methods
Blood samples
A total of 1412 blood samples, including 388 from MN patients, 524 from patients with non-hematological neoplasms (non-HNs), and 500 from healthy control subjects, taken between November 2016 and December 2019 in Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, were included in the study.
MN patients were enrolled from the Department of Hematology and diagnosed according to 2016 WHO classification criteria [11, 18]. Specimens were collected at first diagnosis prior to chemotherapy or recurrence. Data from each individual was included in the study only once and MN patients without complete data were excluded. Characteristics of all MN patients are shown in Table 1. Non-HN patients were enrolled from departments other than hematology, including 284 from internal medicine, 177 from surgery, and 63 from ophthalmology, otolaryngology, stomatology, gynecology, neurology, dermatology, or traditional Chinese medicine. Non-HN patients included 109 with inflammation from respiratory medicine, intensive care unit, and rheumatology and surgery department, and 68 undergoing recombinant human G-CSF administration from the oncology department. Healthy individuals were enrolled from the physical examination center with the exclusion of pregnant women.
Anticoagulant PB samples were taken with EDTA (Becton Dickinson, San Jose, USA) for routine blood analysis. The study was approved by the medical Ethics Committee of Shandong Provincial Hospital (No.2016-KY-051).
Sample analysis
The fully automated Sysmex XN series employs the automated hematology analyzer, XN-9000 (Sysmex, Kobe, Japan), equipped with 00-19E (Build 2) IPU version and the automated slide making/staining device, Sysmex SP-10 (Sysmex, Kobe, Japan). Annual calibration of the XN analyzer was performed, and precision, linearity, carryover, and stability were evaluated regularly. Measurement uncertainty, the dispersion of the measured value reasonably assigned by the characterization, was 0.03 × 109/L for IG# from XN, 0.2% for IG% from XN, and 0.8% for IG% from manual methods. Two levels of blood XN check™ were conducted daily to monitor equipment performance and incorporated into the Sysmex program for real-time quality control. All MN and non-HN PB samples were initially analyzed by XN-9000; blood smears were made and stained using SP-10 and Wright Giemsa (Muto Pure Chemicals, Tokyo, Japan). Control samples were assayed by XN-9000, only, and no blood smears made. All samples were analyzed within 4 h of collection. All threshold values of Q-flags (“IG present”, “Left shift”, “Blast”, “Abn lympho”, and “Atypical lympho”) were set at 100. The WBC#, RBC#, HGB#, PLT#, IG#, IG%, instrument flags, and WDF scattergrams of all samples were recorded.
Two experienced technologists manually classified 200 cells per smear using an Olympus BX53 microscope according to the Clinical and Laboratory Standards Institute (CLSI) H20-A2 [19]. The mean IG%, composed of promyelocytes, myelocytes, and metamyelocytes, calculated by the 2 technologists was considered to be the final result. In the event of significant differences between the results from the 2 technologists, a third technologist classified the slide.
Statistical analysis
Non-parametrical tests (Mann–Whitney test) were performed to compare IG parameters between 2 different groups and the Kruskal–Wallis test to compare 3 or more groups. Spearman rank correlation coefficient analysis was used to evaluate the relationship between IG% values obtained from the Sysmex XN analyzer and from manual assessment. Values for r coefficients < 0.30 were considered to present negligible correlations; 0.30–0.50 low correlations; 0.50–0.70 moderate correlations; 0.70–0.90 strong correlations; and ≥ 0.90 a very high correlation [20]. Bland–Altman bias analysis was performed to compare IG% differences from the two methods. Receiver operating characteristic (ROC) curve analysis was conducted to estimate sensitivity, specificity, and cut-off value for IG parameters assayed by XN analyzer. Pairwise comparisons of the area under the ROC curves (AUCs) were performed using Z-test.
MedCalc Software 19.1 (Ostend, Belgium) and IBM SPSS Statistics 18.0.0 (Chicago, USA) were used. A value of p < 0.05 was considered to be statistically significant.
Results
Comparison of XN-derived IG# and IG% values and manually-derived IG% in PB from MN, non-HN and control subjects
Increased IG# (both p < 0.0001) and IG% (both p < 0.0001) from XN series measurements were observed in MN and non-HN patients when compared with healthy controls (Fig. 1). IG% in healthy controls was not analyzed manually as the positive ratios were too low. Subgroups of patients with inflammation and receiving G-CSF showed higher levels of IG# and IG% from XN analysis plus IG% from manual measurements than the entire group of non-HN patients (all p < 0.0001; Fig. 1). Subgroups of MN patients with MPN (CML and PMF) showed the highest levels of XN-derived IG# and IG% values and also IG% from manual measurements (all p < 0.0001) when compared with other subgroups (Fig. 1).
Correlations and differences between XN and manual estimates of IG% in MN and non-HN patients
Strong correlations between XN- and manually derived IG% values were found in both MN and non-HN patients (Table 2). Although correlations were statistically significant in all groups of patients with AML, MPN, MDS, and MDS/MPN, only moderate correlations were shown for AML patients (Table 2).
Differences between XN- and manually derived IG% values were compared using Bland–Altman bias analysis, and differences for both MN and non-HN patients were considered clinically insignificant (Fig. 2). However, a relatively high difference in the mean and in the 95% CI of limits of agreement (LoA) was shown in the G-CSF subgroup (Fig. 2).
Analysis of ROC curve and cut-off values of XN IG# and IG% from MN and non-HN patients
ROC analysis was performed to assess XN-derived values of IG# and IG% in detection of IGs in PB. IG% values from manual inspection were regarded as the gold standard against which the IG# and IG% values from XN measurements were compared. The AUCs of XN-derived IG# and IG% values were above 0.8 for both MN and non-HN patients, indicating a good level of detection (Table 3). Comparison of the AUCs for XN-derived IG# and IG% values for MN patients revealed that the IG% values showed better efficiency than IG# (p < 0.05). Both the XN-derived IG# and IG% parameters showed higher efficiency in non-HN than in MN patients (p < 0.05). The Youden index gave cut-off values of 0.200 × 109/L for IG# and 1.95% for IG% (Table 3).
Discussion
IGs are often found in the PB of patients with acute infection, inflammation, acute hemorrhage, and those receiving G-CSF. The non-HN patients enrolled in the current study included a number of patients with these conditions accounting for the finding that IG levels among non-HN patients were higher than those of controls.
IGs are easily distinguishable from mature leukocytes in the WDF channel due to their larger nuclear volume and higher fluorescent intensity. This observation underlies the strong correlations between IG% values measured by XN and those from manual inspection in non-HN and MN PB samples. However, morphological abnormalities of immature and mature granulocytes confuse the identification of IGs, resulting in inaccurate counts.
Overall comparisons of WDF scattergrams revealed that inconsistencies between IG% values from XN and manual measurements were usually due to inaccurate IG gating in the scattergram (Supplemental Fig. S1). Granulocytes with morphological abnormalities could be identified in blood smears from all of the inconsistent cases (Supplemental Fig. S2). This phenomenon was observed among samples from patients with acute promyelocytic leukemia (APL), acute myelomonocytic leukemia (AML-M4), and acute monoblastic and monocytic leukemia (AML-M5). The 2015 International Council for Standardization in Haematology (ICSH) recommended that abnormal promyelocytes in APL samples should be counted as blast equivalents rather than as IGs [1]. In addition, neutrophil dysplasia, such as hypogranulation and hyposegmentation, may also be present in AML samples [1, 11] and might interfere with IG gating, leading to inconsistencies. Moreover, “left shift”, arising from elevation of percentages of band neutrophils (> 5%) and cells with hypergranulation, vacuolation, and cytosolic Dӧhle bodies [1, 21], often follows G-CSF administration and may interfere with the intelligent software system gating and falsely raise IG count.
In summary, the IG parameters derived from Sysmex XN hematology analyzer efficiently indicate the presence of IG in PB of MN patients, and this approach may facilitate screening for MNs. In addition, inaccuracies in XN-derived IG parameter measurements may arise due to the presence of granulocytes with morphological abnormalities in PB samples.
Availability of data and material
Available on request.
Change history
17 February 2024
In the Methods section, “ophalmology” and “othlaryngology” should read “ophthalmology” and “otolaryngology.”
References
Palmer L, Briggs C, McFadden S, Zini G, Burthem J, Rozenberg G et al (2015) ICSH recommendations for the standardization of nomenclature and grading of peripheral blood cell morphological features. Int J Lab Hematol 37:287–303
Fowlie PWSB (1998) Diagnostic tests for bacterial infection from birth to 90 days–a systematic review. Arch Dis Child Fetal Neonatal Ed 78:F92-98
Fernández-Suárez APV, Gimenez MT, Hernández JF (2003) Immature granulocyte detection by the SE-9000 haematology analyser during pregnancy. Clin Lab Haematol 25:347–351
Blazkova J, Gupta S, Liu Y, Gaudilliere B, Ganio EA, Bolen CR et al (2017) Multicenter systems analysis of human blood reveals immature neutrophils in males and during pregnancy. J Immunol 198:2479–2488
Nigro KG, O’Riordan M, Molloy EJ, Walsh MC, Sandhaus LM (2005) Performance of an automated immature granulocyte count as a predictor of neonatal sepsis. Am J Clin Pathol 123:618–624
Cimenti C, Erwa W, Herkner KR, Kasper DC, Muller W, Resch B (2012) The predictive value of immature granulocyte count and immature myeloid information in the diagnosis of neonatal sepsis. Clin Chem Lab Med 50:1429–1432
Karon BS, Tolan NV, Wockenfus AM, Block DR, Baumann NA, Bryant SC et al (2017) Evaluation of lactate, white blood cell count, neutrophil count, procalcitonin and immature granulocyte count as biomarkers for sepsis in emergency department patients. Clin Biochem 50:956–958
Yoo J, Ahn SS, Jung SM, Song JJ, Park YB, Lee SW (2018) Delta neutrophil index is associated with vasculitis activity and risk of relapse in ANCA-associated vasculitis. Yonsei Med J 59:397–405
Zhong H, Yazdanbakhsh K (2018) Hemolysis and immune regulation. Curr Opin Hematol 25:177–182
Park SH, Park CJ, Kim MJ, Han MY, Lee BR, Cho YU et al (2016) Evaluation of parameters obtained from the Sysmex XN-2000 for predicting the recovery of the absolute neutrophil count and platelets after hematopoietic stem cell transplantation. Int J Lab Hematol 38:198–208
Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127:2391–2405
Carulli G (1997) Effects of recombinant human granulocyte colony-stimulating factor administration on neutrophil phenotype and functions. Haematologica 82:606–616
Vadhan-Raj SKM, LeMaistre A, Hittelman WN, McCredie K, Trujillo JM, Broxmeyer HE et al (1987) Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. N Engl J Med 317:1545–1552
Field D, Taube E, Heumann S (2006) Performance evaluation of the immature granulocyte parameter on the Sysmex XE-2100 automated hematology analyzer. Lab Hematol 12:11–14
Seo JY, Lee ST, Kim SH (2015) Performance evaluation of the new hematology analyzer Sysmex XN-series. Int J Lab Hematol 37:155–164
Redin ME, Vives A, Garrido A, Urrechaga E, Lacasta M (2016) Local verification between the hematological analyzers Sysmex XN-series and XE-5000. Int J Lab Hematol 38:256–264
Schoorl M, Schoorl M, Chevallier M, Urrechaga E, Lacasta M (2017) Multicenter verification of the Sysmex XN-Series. Int J Lab Hematol 39:489–496
Swerdlow SH, Campo E, Pileri SA, Stein H, Siebert R, Advani R et al (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127:2375–2390
Clinical Laboratory Standards Institute (2007) Reference leukocyte (WBC) differential count (proportional) and evaluation of instrumental methods; approved standard, 2nd edn, Wayne, CLSI
Mukaka MM (2012) Statistics corner: A guide to appropriate use of correlation coefficient in medical research. Malawi Med J 24:69–71
Prokocimer M, Potasman I (2008) The added value of peripheral blood cell morphology in the diagnosis and management of infectious diseases–part 1: basic concepts. Postgrad Med J 84:579–585
Maenhout TM, Marcelis L (2014) Immature granulocyte count in peripheral blood by the Sysmex haematology XN series compared to microscopic differentiation. J Clin Pathol 67:648–650
Briggs CJ, Linssen J, Longair I, Machin SJ (2011) Improved flagging rates on the Sysmex XE-5000 compared with the XE-2100 reduce the number of manual film reviews and increase laboratory productivity. Am J Clin Pathol 136:309–316
Acknowledgements
The authors would like to express their gratitude to EditSprings (https://www.editsprings.cn/) for the expert linguistic services provided.
Funding
This work was supported by Natural Science Foundation of Shandong Province, China, under Grant (No.ZR2017MH088).
Author information
Authors and Affiliations
Contributions
Yajuan Shen conceptualized, designed, and supervised the study and also drafted the manuscript; Qifeng Lu analyzed data and edited the manuscript; Tian Li and Tingting Hou provided interpreting data; Ying Li participated in discussing the conception and manuscript; Yajuan Zhao, Shu Feng, Xixian Yang, and Mengyu Zhu sorted out data.
Corresponding author
Ethics declarations
Ethics approval
This study was approved by the medical Ethics Committee of Shandong Provincial Hospital (No.2016-KY-051).
Consent to participate
This study was conducted only after taking informed consent from all participants.
Consent for publication
All the authors gave their consent for submission/publication of this manuscript.
Conflict of interest
The authors declare no competing interests.
95% CIa 95% confidence intervals.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
12308_2022_484_MOESM1_ESM.jpg
Supplemental Figure S1: InaccurateIG gating in APL, AML-M4 and G-CSF administration WDF scattergrams. Dark bluedots in circles are identified as IGs by Sysmex XN. APL: acute promyelocytic leukemia;AML-M4: acute myelomonocytic leukemia. (JPG 229 KB)
12308_2022_484_MOESM2_ESM.jpg
SupplementalFigure S2: Morphological granulocyte abnormalities in PB from APL, AML-M4 andG-CSF treated patients. Blood smears are magnified x1000 and visualized with WrightGiemsa stain. Red arrow points: abnormal promyelocytes; white arrow points: hypogranulatedneutrophils; blue arrow points: hypergranulated neutrophils. (JPG 180 KB)
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Lu, Q., Li, Y., Li, T. et al. Evaluation of immature granulocyte parameters in myeloid neoplasms assayed by Sysmex XN hematology analyzer. J Hematopathol 15, 1–6 (2022). https://doi.org/10.1007/s12308-022-00484-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12308-022-00484-w